Abstract
Oxymetazoline 1% cream (Rhofade™) is a topical α1A-agonist approved to treat persistent facial erythema associated with rosacea in adults in the USA. It relieves the redness of affected skin by inducing vasoconstriction in the superficial skin vasculature. In clinical trials, application of oxymetazoline cream for up to 1 year was effective and generally well tolerated in rosacea patients with persistent erythema, with a low incidence of application-site reactions and rebound erythema.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
